GOSSAMER BIO INC (GOSS)
US38341P1021 - Common Stock
ChartMill assigns a Buy % Consensus number of 81% to GOSS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.76. This target is 841.66% above the current price.
GOSS was analyzed by 16 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about GOSS.
In the previous month the buy percentage consensus was at a similar level.
GOSS was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-06-25 | Oppenheimer | Initiate | Outperform |
| 2024-06-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-08 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-03-06 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-03-06 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-19 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-11-10 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-08-11 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-26 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-21 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-05-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-21 | Barclays | Maintains | Equal-Weight |
| 2023-03-07 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-03-01 | Guggenheim | Initiate | Neutral |
| 2022-12-08 | HC Wainwright & Co. | Maintains | Buy |
| 2022-12-07 | SMBC Nikko | Downgrade | Outperform -> Neutral |
| 2022-12-07 | UBS | Maintains | Buy |
| 2022-12-07 | SVB Leerink | Maintains | Outperform |
| 2022-12-07 | Barclays | Downgrade | Overweight -> Equal-Weight |